Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Study Evaluating the Addition of Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia

NCT00427791 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00427791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00427791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Study Evaluating the Addition of Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
October 31, 2009
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia